A Motley Fool analysis gives three 10-year outcomes for $10,000 invested in AbbVie: $17,908, $23,674 or $31,058 at annual total returns of 6%, 9% or 12%, respectively. These are scenarios, not guarantees; AbbVie’s dividend yield is 2.6% and trailing P/E is 75.
For comparison, the article says $10,000 invested in AbbVie a decade ago, with dividends reinvested, would now be worth $61,425.56, an average annual return of 19.91%. The cautious case reflects patent exposure: 14 AbbVie drugs face expirations through 2031, although only Vraylar was among the company’s top 10 sellers in the second quarter. AbbVie estimates high-single-digit sales growth through the decade.
The 9% case assumes continued execution by Skyrizi and Rinvoq plus mid-single-digit dividend growth; AbbVie raised its dividend 5.5% this year, its 53rd consecutive annual increase. The 12% case depends on newer drugs outperforming. AbbVie reported improved response rates and progression-free survival in a phase 3 etentamig trial for relapsed/refractory multiple myeloma on Sept. 3. It also spent $10.9 billion to acquire Apogee; its zumilokibart candidate could be a blockbuster if it treats other inflammatory conditions.
